- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02257580
The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO
The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)
Study Overview
Status
Intervention / Treatment
Detailed Description
The participating anesthesiologists will not be blinded to study arms and hypotheses. Dr. Christopher Edmonds will be the head anesthesiologist for this study and will administer anesthetics to participants in this trial whenever his schedule makes it possible. Anesthesia will be conducted in a standardized fashion, with IV sedation using Versed and IV propofol, +/- Fentanyl and Ketamine . A Combined Spinal-Epidural (CSE) will be placed using 12.5-20 mg of bupivacaine. If a CSE is unsuccessful and an epidural and/or spinal are successfully obtained, the patient may still be included in the study. Patients not receiving neuraxial anesthesia will be excluded. If a patient requires general anesthesia, it will be induced at this time, but the patient will be excluded from the study. An arterial line and additional venous access will be obtained in standardized sterile practice. Sedation will be maintained with IV propofol. IV Valium, Toradol and IV acetaminophen will be given towards the end of the case, per anesthesiologist's discretion.
The blood pressure target will be 20-25% below baseline, which will be achieved primarily with the neuraxial anesthesia. For blood pressure above this range, the epidural will be dosed with a short-acting local anesthetic, and/or IV sedation will be titrated as per the anesthesiologist's judgment. For hypotension below this range, pressors or intravenous pressors will be given. An IV fluid bolus may also be given in the amount of 10-20cc/kg. Additional maintenance IV fluids will be given to maintain urine output of at least 0.5-1ml/kg/hr. The criteria for transfusion of blood products will be a hemoglobin level of < 7.0 g/dL or a hemoglobin level of < 10.0 g/dL with clinical signs of symptomatic anemia (e.g., unexplained tachycardia, hypotension unresponsive to fluids or vasopressors, change in mental status, low urine output, and shortness of breath). Blood will be administered 1 unit at a time, and the presence of symptoms or signs will be reassessed after each unit. This algorithm may be altered by the treating physician (e.g., PACU attending, surgeon, or the OR anesthesiologist), however all decisions will be supported by reasonable documentation. Drains will be removed on POD 2 unless specified by the attending surgeon. Of note, the chart of the patient will clearly indicate him/her as a study patient; a sticker will be place on the front of each participating patient's chart. Their enrollment will also be communicated in the clinician rounding notes for each patient. Drains will be labeled for each study participant as well, and nurses will record the drain outputs per their floor protocol.
Attending surgeons, orthopedic surgery residents, physician assistants and research assistants involved with this study will assist in data collection. For each patient, we will collect demographic data, pre-operative CBC data, intra-operative cell saver auto-transfusion volumes, post-operative number of packed red blood cell units transfused, post-operative CBC data, post-operative drain outputs, and post-operative complications. This information will be gathered from the peri-operative medical records and electronic medical records. Surgeons and clinical and research personnel will review medical chart and progress notes for evidence of clinically significant VTE, reoperation, hematoma, seroma, and infection.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scheduled for bilateral varus rotational osteotomy (VRO) with or without associated soft tissue and osseous procedures
Exclusion Criteria:
- Preoperative use of an anticoagulant (Plavix, warfarin, lovenox, etc.)
- History of hypersensitivity to EACA
- History of thromboembolic event (e.g., PE or DVT)
- History of renal insufficiency or failure
- Congenital or acquired coagulopathy as evidence by INR >1.4 or PTT > 1.4 times normal, or Platelets <150,000/mm3 on preoperative laboratory testing
- Use of hormone replacement therapy or hormonal contraceptive agents within days prior to surgery
- Use of acetylsalicylic acid (ASA), antiplatelet agents within 7 days prior to surgery
- Pregnant
- Breastfeeding
- Not received neuraxial anesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: E-Aminocaproic acid (EACA)
An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision.
During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained.
The use of EACA will be terminated at the end of the case.
|
E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010}
Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013;
Thompson,2005; Florentino-Pineda,2001}
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Equivalent volume of normal saline prepared by the pharmacy.
|
E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010}
Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013;
Thompson,2005; Florentino-Pineda,2001}
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative Calculated Total Blood Loss
Time Frame: Intraoperative (3-6 hours)
|
Determined by estimated blood volume, calculated using difference in preoperative and postoperative hemoglobin and applied to the Nadler equation for estimating blood volume while adjusting for transfused hemoglobin to produce a single metric of calculated intraoperative blood loss.
|
Intraoperative (3-6 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative Cell Saver Utilization
Time Frame: Intraoperative, 1 day
|
Number of participants requiring 1 unit of intraoperative cell saver transfusion.
Patients either received or did not receive intraoperative cell saver transfusion.
The maximum number of intraoperative units transfused in this study was 1 unit.
The count of participants in the data table refers to the number of patients who received this transfusion.
|
Intraoperative, 1 day
|
Postoperative Allogeneic Blood Transfusion
Time Frame: Post-Surgery, an expected average of 1 week
|
The number of participants that required 1 unit of blood transfused post-operatively.
Patients received blood if necessary post operatively, and the maximum number of units a patient received was 1.
The count of participants refers to the number of patients who received this transfusion unit.
|
Post-Surgery, an expected average of 1 week
|
Post Operative Blood Loss
Time Frame: Post-Surgery, 24 hours
|
24 hour drain output (mL)
|
Post-Surgery, 24 hours
|
Length of Hospital Stay
Time Frame: Post-Surgery, an expected average of 1 week
|
postoperative day of discharge after surgery- day of intake.
|
Post-Surgery, an expected average of 1 week
|
Complications [VTE (Symptomatic of DVT or PE), Infection (Superficial, Deep), Hematoma, Seroma, Reoperation, and Death]
Time Frame: an expected average of 1 week (post-surgery), Follow-up at 6 weeks
|
Incidence of VTE (symptomatic of DVT or PE), infection (superficial, deep), hematoma, seroma, reoperation, and death, measured in person-years ( x cases per 100,000 person years)
|
an expected average of 1 week (post-surgery), Follow-up at 6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: David Scher, MD, Hospital for Special Surgery, New York
Publications and helpful links
General Publications
- Chimento GF, Huff T, Ochsner JL Jr, Meyer M, Brandner L, Babin S. An evaluation of the use of topical tranexamic acid in total knee arthroplasty. J Arthroplasty. 2013 Sep;28(8 Suppl):74-7. doi: 10.1016/j.arth.2013.06.037.
- Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010 Mar;18(3):132-8.
- Faraoni D, Goobie SM. The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: a systematic review of the literature. Anesth Analg. 2014 Mar;118(3):628-36. doi: 10.1213/ANE.0000000000000080.
- McLeod LM, French B, Flynn JM, Dormans JP, Keren R. Antifibrinolytic Use and Blood Transfusions in Pediatric Scoliosis Surgeries Performed at US Children's Hospitals. J Spinal Disord Tech. 2015 Oct;28(8):E460-6. doi: 10.1097/BSD.0b013e3182a22a54.
- Thompson GH, Florentino-Pineda I, Poe-Kochert C. The role of amicar in decreasing perioperative blood loss in idiopathic scoliosis. Spine (Phila Pa 1976). 2005 Sep 1;30(17 Suppl):S94-9. doi: 10.1097/01.brs.0000175188.05542.a9.
- Thompson GH, Florentino-Pineda I, Poe-Kochert C, Armstrong DG, Son-Hing J. Role of Amicar in surgery for neuromuscular scoliosis. Spine (Phila Pa 1976). 2008 Nov 15;33(24):2623-9. doi: 10.1097/BRS.0b013e318187c046.
- Gill JB, Chin Y, Levin A, Feng D. The use of antifibrinolytic agents in spine surgery. A meta-analysis. J Bone Joint Surg Am. 2008 Nov;90(11):2399-407. doi: 10.2106/JBJS.G.01179.
- Florentino-Pineda I, Blakemore LC, Thompson GH, Poe-Kochert C, Adler P, Tripi P. The Effect of epsilon-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. Spine (Phila Pa 1976). 2001 May 15;26(10):1147-51. doi: 10.1097/00007632-200105150-00011.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on E-Aminocaproic Acid
-
Eduardo FerriolliCompletedFatty Acid Deficiency | Nutrient Deficiency | Vitamin E Deficiency | Selenium Deficiency | Age-Related Immunodeficiency | Institutionalization; Disinhibited AttachmentBrazil
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA)CompletedTobacco Smoking | Vaping | Nicotine Administration & Dosage | E-cigarettes | E-LiquidUnited States
-
University of California, San DiegoNot yet recruitingE Cigarette Use
-
Virginia Commonwealth UniversityRecruiting
-
Yale UniversityAmerican Heart AssociationRecruiting
-
University of VirginiaDuke UniversityRecruiting
-
Western University, CanadaLondon Health Sciences CentreNot yet recruiting
-
Veterans Medical Research FoundationUniversity of CaliforniaRecruiting
-
Anna Stanhewicz, PhDRecruiting
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruiting
Clinical Trials on E-Aminocaproic acid
-
Carlos A Acosta-OlivoCompletedBlood Loss, SurgicalMexico
-
Children's National Research InstituteActive, not recruiting
-
Paul StrickerChildren's Anesthesiology Associates, Ltd.; Thomas B. and Jeannette E. Laws...Completed
-
Heekin Orthopedic Research InstituteUnknown
-
The University of Texas Health Science Center at...WithdrawnIntracerebral Hemorrhage
-
University of RochesterCompleted
-
Emory UniversityTerminatedThrombocytopenia | Hematological MalignanciesUnited States
-
University of PennsylvaniaTerminatedAortic DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedScoliosis | Spondylitis | Spinal Stenosis | Kyphosis | LordosisUnited States
-
Miller Orthopedic SpecialistsCHI Health Mercy Hospital; Creighton University Medical CenterCompletedOsteoarthritisUnited States